- Home
- NPCE vs CBIO Comparison
NPCE vs CBIO Comparison
Compare NPCE & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- CBIO
- Stock Information
- Founded
- NPCE 1997
- CBIO 2003
- Country
- NPCE United States
- CBIO United States
- Employees
- NPCE N/A
- CBIO N/A
- Industry
- NPCE Medical Specialities
- CBIO
- Sector
- NPCE Health Care
- CBIO
- Exchange
- NPCE Nasdaq
- CBIO Nasdaq
- Market Cap
- NPCE 292.9M
- CBIO 308.0M
- IPO Year
- NPCE 2021
- CBIO N/A
- Fundamental
- Price
- NPCE $9.15
- CBIO $14.29
- Analyst Decision
- NPCE Strong Buy
- CBIO Strong Buy
- Analyst Count
- NPCE 6
- CBIO 5
- Target Price
- NPCE $16.67
- CBIO $25.60
- AVG Volume (30 Days)
- NPCE 205.3K
- CBIO 98.3K
- Earning Date
- NPCE 08-12-2025
- CBIO 07-31-2025
- Dividend Yield
- NPCE N/A
- CBIO N/A
- EPS Growth
- NPCE N/A
- CBIO N/A
- EPS
- NPCE N/A
- CBIO N/A
- Revenue
- NPCE $88,570,000.00
- CBIO N/A
- Revenue This Year
- NPCE $22.13
- CBIO N/A
- Revenue Next Year
- NPCE $6.07
- CBIO N/A
- P/E Ratio
- NPCE N/A
- CBIO N/A
- Revenue Growth
- NPCE 23.32
- CBIO N/A
- 52 Week Low
- NPCE $5.45
- CBIO $10.83
- 52 Week High
- NPCE $18.98
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- NPCE 51.74
- CBIO 52.92
- Support Level
- NPCE $8.61
- CBIO $13.50
- Resistance Level
- NPCE $8.99
- CBIO $16.00
- Average True Range (ATR)
- NPCE 0.53
- CBIO 0.79
- MACD
- NPCE 0.11
- CBIO 0.16
- Stochastic Oscillator
- NPCE 75.00
- CBIO 39.68
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.